SEARCH:   Advanced

Blood, 15 January 2007, Vol. 109, No. 2, pp. 492-496. Prepublished online as a Blood First Edition Paper on September 7, 2006; DOI 10.1182/blood-2006-07-030544. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-030544v1 109/2/492    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sanchorawala, V. Articles by Seldin, D. C. Search for Related Content PubMed PubMed Citation Articles by Sanchorawala, V. Articles by Seldin, D. C. Related Collections Immunobiology Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial Vaishali Sanchorawala1,2,, Daniel G. Wright1,2, Michael Rosenzweig1,2, Kathleen T. Finn1, Salli Fennessey1, Jerome B. Zeldis3, Martha Skinner2, and David C. Seldin1,2 1 Section of Hematology/Oncology of Department of Medicine, Boston University Medical Center, MA; 2 Amyloid Treatment and Research Program, Boston University Medical Center, MA; 3 Celgene, Summit, NJ In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage vital organs. Treatment regimens used in multiple myeloma can be effective in AL amyloidosis; however, patients with this disease often tolerate these regimens poorly because of multisystem organ dysfunction. Thalidomide and lenalidomide have both been shown to be effective in myeloma. In this report, we describe results of a phase 2 trial of the use of lenalidomide, as a single agent and in combination with dexamethasone, for the treatment of AL amyloidosis. Thirty-four patients with AL amyloidosis, most with prior therapies, were enrolled in the trial. The initial dose of lenalidomide used (25 mg/d) was poorly tolerated; however, a reduced dose of 15 mg/d was generally well tolerated. Of 24 evaluable patients, 7 (29%) achieved a hematologic complete response and 9 (38%) achieved a partial hematologic response, for an overall hematologic response rate of 67%. Hematologic responses were also associated with clinical responses. Fatigue and myelosuppression were the most common treatment-related adverse events (35%), while thromboembolic complications (9%) were the most serious. Findings from this trial indicate that lenalidomide can be effective in treating AL amyloidosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A triple on AL amyloidosis, waiting for a home run Geraldine P. Schechter Blood 2007 109: 391-392. [Full Text] [PDF] This article has been cited by other articles: L. M. Dember Modern Treatment of Amyloidosis: Unresolved Questions J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472. [Abstract] [Full Text] [PDF] S. O. Schonland, N. Kroger, C. Wolschke, P. Dreger, A. D. Ho, and U. Hegenbart Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect" Haematologica, March 1, 2009; 94(3): 439 - 441. [Full Text] [PDF] A. Solomon, S. D. Macy, C. Wooliver, D. T. Weiss, and P. Westermark Splenic plasma cells can serve as a source of amyloidogenic light chains Blood, February 12, 2009; 113(7): 1501 - 1503. [Abstract] [Full Text] [PDF] P. Zhou, R. L. Comenzo, A. B. Olshen, E. Bonvini, S. Koenig, P. G. Maslak, M. Fleisher, J. Hoffman, S. Jhanwar, J. W. Young, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy Blood, April 1, 2008; 111(7): 3403 - 3406. [Abstract] [Full Text] [PDF] A. A. Chanan-Khan and B. D. Cheson Lenalidomide for the Treatment of B-Cell Malignancies J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552. [Abstract] [Full Text] [PDF] A. D. Wechalekar, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease Haematologica, February 1, 2008; 93(2): 295 - 298. [Abstract] [Full Text] [PDF] N. Chen, H. Lau, L. Kong, G. Kumar, J. B. Zeldis, R. Knight, and O. L. Laskin Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis J. Clin. Pharmacol., December 1, 2007; 47(12): 1466 - 1475. [Abstract] [Full Text] [PDF] V. Sanchorawala, M. Skinner, K. Quillen, K. T. Finn, G. Doros, and D. C. Seldin Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Blood, November 15, 2007; 110(10): 3561 - 3563. [Abstract] [Full Text] [PDF] R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF] E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF] G. Merlini Refining therapy for AL amyloidosis Blood, December 1, 2006; 108(12): 3632 - 3633. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020